Product Name
TTBK2, siRNA
Full Product Name
TTBK2 siRNA (Human)
Product Synonym Names
KIAA0847; Tau-tubulin kinase 2
Product Gene Name
TTBK2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q6IQ55
Specificity
TTBK2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human TTBK2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of TTBK2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
TTBK2 sirna
siRNA to inhibit TTBK2 expression using RNA interference
Applications Tested/Suitable for TTBK2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for TTBK2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_775771.3
[Other Products]
NCBI GenBank Nucleotide #
NM_173500.3
[Other Products]
UniProt Primary Accession #
Q6IQ55
[Other Products]
UniProt Secondary Accession #
O94932; Q6ZN52; Q8IVV1[Other Products]
UniProt Related Accession #
Q6IQ55[Other Products]
Molecular Weight
54,037 Da
NCBI Official Full Name
tau-tubulin kinase 2
NCBI Official Synonym Full Names
tau tubulin kinase 2
NCBI Official Symbol
TTBK2??[Similar Products]
NCBI Official Synonym Symbols
TTBK; SCA11
??[Similar Products]
NCBI Protein Information
tau-tubulin kinase 2
UniProt Protein Name
Tau-tubulin kinase 2
Protein Family
Tau-tubulin kinase
UniProt Gene Name
TTBK2??[Similar Products]
UniProt Synonym Gene Names
KIAA0847??[Similar Products]
UniProt Entry Name
TTBK2_HUMAN
NCBI Summary for TTBK2
This gene encodes a serine-threonine kinase that putatively phosphorylates tau and tubulin proteins. Mutations in this gene cause spinocerebellar ataxia type 11 (SCA11); a neurodegenerative disease characterized by progressive ataxia and atrophy of the cerebellum and brainstem. [provided by RefSeq, Aug 2009]
UniProt Comments for TTBK2
TTBK2: Serine/threonine kinase which is able to phosphorylate tau on serines. Defects in TTBK2 are the cause of spinocerebellar ataxia type 11 (SCA11). Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA11 is an autosomal dominant cerebellar ataxia (ADCA). It is a relatively benign, late-onset, slowly progressive neurologic disorder. Belongs to the protein kinase superfamily. CK1 Ser/Thr protein kinase family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Protein kinase, Ser/Thr (non-receptor); EC 2.7.11.1; Protein kinase, CK1; Kinase, protein; CK1 group; TTBK family
Chromosomal Location of Human Ortholog: 15q15.2
Cellular Component: centriole; extracellular space; nucleus; cytosol
Molecular Function: protein serine/threonine kinase activity; protein binding; ATP binding
Biological Process: regulation of cell shape; smoothened signaling pathway; peptidyl-serine phosphorylation; organelle organization and biogenesis; cilium biogenesis
Disease: Spinocerebellar Ataxia 11
Research Articles on TTBK2
1. TTBK2 bound EB1 and Cep164 through its SxIP motifs and a proline-rich motif, respectively.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
